Oral Analgesic Use in Postmenopausal Women After Curative Breast Cancer Treatment: Post Hoc Analysis of the ATAC Trial

Abstract

<jats:p> Aim: To evaluate analgesic use and associated conditions in postmenopausal women who had undergone curative breast cancer treatment. Materials &amp; methods: This post hoc analysis used the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial database, which included patient reports of concomitant medications and associated indications during follow-up. Results: Of 3434 women with eligible concomitant medication data, 71.8% reported oral analgesic use. Of 2321 patients using analgesics ≥30 days, 47.9% reported opioid use. Musculoskeletal pain was the most common indication for oral analgesic use. Of patients using opioids, 28.1% reported concomitant laxative use. Conclusion: Approximately half of the patients reported opioid use, most commonly for noncancer (musculoskeletal) pain, suggesting that breast cancer survivors experience chronic pain that should be appropriately managed. </jats:p>